← Viking Therapeutics overview

Viking Therapeutics vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Viking Therapeutics Inc (VKTX)

Q3 2026
▲2▼1

Viking's VK2735 shines, but cash burn and dilution weigh

  • VK2735 efficacy and dosing VK2735 showed 22% weight loss and up to 97% maintained on less-frequent dosing, strong efficacy plus convenience that positions it against Lilly and Novo.

    This is the key new clinical data that drove optimism in the quarter.

  • Takeover speculation Vertex's $10B Crinetics deal fueled takeover speculation, and an unsettled oral GLP-1 market keeps Viking's pipeline valuable.

    This new external event increased investor interest in Viking as a potential acquisition target.

  • Widening losses and dilution Q2 net loss widened to $128.1M as R&D surged, and an upsized $500M stock and convertible note offering raises dilution concerns.

    These new financial developments create a real counterweight to the positive pipeline news.

  • Long wait and valuation divide Phase 3 data remain years away, and analyst valuations diverge wildly ($92.72 vs. $14.02). Cash burn and funding needs will likely overhang the stock until VK2735 reaches market.

    This highlights the ongoing uncertainty and long timeline that keep the stock volatile.

August 2026
▲2▼1

Viking's VK2735 data wows, but $500M raise dilutes

  • VK2735 maintenance data: 22% weight loss, up to 97% kept on less-frequent dosing Viking reported that its obesity drug VK2735 produced 22% weight loss and patients kept up to 97% of it when switched to every-other-week shots (90% monthly), versus 61% on placebo. This is the big driver: strong efficacy plus a more convenient schedule makes the drug a real contender against Lilly and Novo, lifting hopes for future sales and partnership or buyout interest.

    This is the single biggest new event moving VKTX, directly boosting its competitive position and long-term value.

  • Upsized $500M stock and convertible note offering raises dilution worries Viking priced an upsized raise: 7.85 million shares at $35 plus $225 million of convertible notes, up from $200 million each. The cash funds VK2735 and VK3019 trials, but selling new shares dilutes existing owners and the convertible notes could dilute later. This is the main counterweight to the good data.

    It is the key new financing event that pressures the stock by diluting current shareholders.

  • Big pharma GLP-1 race leaves room for Viking Lilly's Mounjaro and Zepbound sales surged while Novo's Ozempic and Wegovy stalled, and Lilly's oral pill Foundayo is just starting. Viking's oral VK2735 phase 3 is planned for late 2026. A fast-growing market with an unsettled oral segment keeps Viking's pipeline valuable, supporting the stock.

    It shows the competitive landscape that makes Viking's oral and injectable programs strategically valuable.

  • Cash burn and capital needs remain the overhang Viking used about $96 million last quarter and cash fell to $502 million from $706 million. Management says cash lasts into 2028, but the new raise confirms trials are expensive. Until VK2735 reaches market, funding needs and dilution risk will keep weighing on the stock even as data improves.

    It explains the persistent financial pressure that offsets clinical optimism for VKTX.

Latest
▲2▼1

Viking's VK2735 data wows, but $500M raise dilutes

  • VK2735 maintenance data: 22% weight loss, up to 97% kept on less-frequent dosing Viking reported that its obesity drug VK2735 produced 22% weight loss and patients kept up to 97% of it when switched to every-other-week shots (90% monthly), versus 61% on placebo. This is the big driver: strong efficacy plus a more convenient schedule makes the drug a real contender against Lilly and Novo, lifting hopes for future sales and partnership or buyout interest.

    This is the single biggest new event moving VKTX, directly boosting its competitive position and long-term value.

  • Upsized $500M stock and convertible note offering raises dilution worries Viking priced an upsized raise: 7.85 million shares at $35 plus $225 million of convertible notes, up from $200 million each. The cash funds VK2735 and VK3019 trials, but selling new shares dilutes existing owners and the convertible notes could dilute later. This is the main counterweight to the good data.

    It is the key new financing event that pressures the stock by diluting current shareholders.

  • Big pharma GLP-1 race leaves room for Viking Lilly's Mounjaro and Zepbound sales surged while Novo's Ozempic and Wegovy stalled, and Lilly's oral pill Foundayo is just starting. Viking's oral VK2735 phase 3 is planned for late 2026. A fast-growing market with an unsettled oral segment keeps Viking's pipeline valuable, supporting the stock.

    It shows the competitive landscape that makes Viking's oral and injectable programs strategically valuable.

  • Cash burn and capital needs remain the overhang Viking used about $96 million last quarter and cash fell to $502 million from $706 million. Management says cash lasts into 2028, but the new raise confirms trials are expensive. Until VK2735 reaches market, funding needs and dilution risk will keep weighing on the stock even as data improves.

    It explains the persistent financial pressure that offsets clinical optimism for VKTX.

July 2026
▲2▼1

Viking's Obesity Pipeline Advances, But Cash Burn and Valuation Risks Loom

  • VK2735 Phase 2 Shows Rapid Weight Loss, Phase 3 Data Years Away VK2735 delivered mid-teens percentage weight loss in 13 weeks, faster than oral rivals. Phase 3 results are due mid-to-late 2027, with oral data in 2028-2029. This keeps the potential $100 billion market in play, supporting Viking's valuation, but the long timeline means no near-term revenue.

    This is the core clinical update that drives Viking's long-term value and investor optimism.

  • Vertex's $10B Crinetics Deal Fuels Takeover Speculation for Viking Vertex's acquisition of Crinetics for $10 billion has reignited M&A interest in obesity drugmakers. Viking, with its late-stage VK2735 and early VK3019, is seen as a prime target. A buyout could offer a premium, but any deal depends on upcoming data and remains speculative.

    M&A speculation can significantly boost Viking's stock price by implying a potential buyout premium.

  • Q2 2026 Net Loss Widens to $128.1 Million as R&D Spending Surges Viking reported a $128.1 million net loss, more than double last year's, with R&D expenses up to $115.8 million. Cash fell to $502 million from $706 million. This rising cash burn increases the risk of future dilution or financing, pressuring the stock.

    The widening loss and shrinking cash highlight the financial strain of funding late-stage trials, a key risk for a pre-revenue company.

  • Analyst Valuation Gap: 120% Undervalued vs. DCF Overvalued One analyst narrative sees Viking 120% undervalued at $92.72 per share, while a DCF model suggests it's overvalued at $14.02. This huge discrepancy reflects uncertainty over pipeline success and funding needs, making the stock volatile and hard to value.

    The stark valuation divide shows the market's uncertainty about Viking's prospects, which can cause sharp price swings.

▲2▼1

Viking's Obesity Pipeline Advances, But Cash Burn and Valuation Risks Loom

  • VK2735 Phase 2 Shows Rapid Weight Loss, Phase 3 Data Years Away VK2735 delivered mid-teens percentage weight loss in 13 weeks, faster than oral rivals. Phase 3 results are due mid-to-late 2027, with oral data in 2028-2029. This keeps the potential $100 billion market in play, supporting Viking's valuation, but the long timeline means no near-term revenue.

    This is the core clinical update that drives Viking's long-term value and investor optimism.

  • Vertex's $10B Crinetics Deal Fuels Takeover Speculation for Viking Vertex's acquisition of Crinetics for $10 billion has reignited M&A interest in obesity drugmakers. Viking, with its late-stage VK2735 and early VK3019, is seen as a prime target. A buyout could offer a premium, but any deal depends on upcoming data and remains speculative.

    M&A speculation can significantly boost Viking's stock price by implying a potential buyout premium.

  • Q2 2026 Net Loss Widens to $128.1 Million as R&D Spending Surges Viking reported a $128.1 million net loss, more than double last year's, with R&D expenses up to $115.8 million. Cash fell to $502 million from $706 million. This rising cash burn increases the risk of future dilution or financing, pressuring the stock.

    The widening loss and shrinking cash highlight the financial strain of funding late-stage trials, a key risk for a pre-revenue company.

  • Analyst Valuation Gap: 120% Undervalued vs. DCF Overvalued One analyst narrative sees Viking 120% undervalued at $92.72 per share, while a DCF model suggests it's overvalued at $14.02. This huge discrepancy reflects uncertainty over pipeline success and funding needs, making the stock volatile and hard to value.

    The stark valuation divide shows the market's uncertainty about Viking's prospects, which can cause sharp price swings.

Q2 2026
▲4

Viking's Obesity Pipeline Advances as Medicare Coverage Boosts Sector

  • Medicare GLP-1 Bridge coverage begins Starting July 1, 2026, Medicare's GLP-1 Bridge program covers anti-obesity drugs like Wegovy and Zepbound. This expands the market for weight-loss treatments, boosting demand expectations for Viking's VK2735 if approved. The news helped extend Viking's stock winning streak to eight days.

    New Medicare coverage directly expands the addressable market for Viking's obesity drug, a key demand driver.

  • VK3019 enters first human trial Viking started a Phase 1 trial of VK3019, a new class of weight-loss drug using a different mechanism than GLP-1s. This expands the pipeline beyond VK2735, potentially offering another growth driver. However, it adds development costs for a pre-revenue company.

    New clinical milestone for a second obesity candidate diversifies Viking's pipeline and future revenue potential.

  • VK2735 Phase 3 data expected 2027 Viking's lead obesity drug VK2735 is in Phase 3 trials, with top-line data expected no earlier than 2027. Phase 2 results showed up to 14.7% weight loss, competitive but behind rivals like Eli Lilly's retatrutide (28.3%). Success could unlock a $100 billion market.

    The timing and potential of VK2735's Phase 3 data are central to Viking's valuation and investor expectations.

  • Stock gained 19.2% in June on pipeline optimism Viking shares rose 19.2% in June as investors grew optimistic about the weight-loss pipeline. The rally was fueled by Phase 2 results, pipeline advancements, and sector tailwinds. However, the stock remains volatile and high-risk, with no approved products yet.

    Summarizes the period's strong stock performance and the underlying drivers, giving a big-picture view.

June 2026
▲4

Viking's Obesity Pipeline Advances as Medicare Coverage Boosts Sector

  • Medicare GLP-1 Bridge coverage begins Starting July 1, 2026, Medicare's GLP-1 Bridge program covers anti-obesity drugs like Wegovy and Zepbound. This expands the market for weight-loss treatments, boosting demand expectations for Viking's VK2735 if approved. The news helped extend Viking's stock winning streak to eight days.

    New Medicare coverage directly expands the addressable market for Viking's obesity drug, a key demand driver.

  • VK3019 enters first human trial Viking started a Phase 1 trial of VK3019, a new class of weight-loss drug using a different mechanism than GLP-1s. This expands the pipeline beyond VK2735, potentially offering another growth driver. However, it adds development costs for a pre-revenue company.

    New clinical milestone for a second obesity candidate diversifies Viking's pipeline and future revenue potential.

  • VK2735 Phase 3 data expected 2027 Viking's lead obesity drug VK2735 is in Phase 3 trials, with top-line data expected no earlier than 2027. Phase 2 results showed up to 14.7% weight loss, competitive but behind rivals like Eli Lilly's retatrutide (28.3%). Success could unlock a $100 billion market.

    The timing and potential of VK2735's Phase 3 data are central to Viking's valuation and investor expectations.

  • Stock gained 19.2% in June on pipeline optimism Viking shares rose 19.2% in June as investors grew optimistic about the weight-loss pipeline. The rally was fueled by Phase 2 results, pipeline advancements, and sector tailwinds. However, the stock remains volatile and high-risk, with no approved products yet.

    Summarizes the period's strong stock performance and the underlying drivers, giving a big-picture view.

▲4

Viking's Obesity Pipeline Advances as Medicare Coverage Boosts Sector

  • Medicare GLP-1 Bridge coverage begins Starting July 1, 2026, Medicare's GLP-1 Bridge program covers anti-obesity drugs like Wegovy and Zepbound. This expands the market for weight-loss treatments, boosting demand expectations for Viking's VK2735 if approved. The news helped extend Viking's stock winning streak to eight days.

    New Medicare coverage directly expands the addressable market for Viking's obesity drug, a key demand driver.

  • VK3019 enters first human trial Viking started a Phase 1 trial of VK3019, a new class of weight-loss drug using a different mechanism than GLP-1s. This expands the pipeline beyond VK2735, potentially offering another growth driver. However, it adds development costs for a pre-revenue company.

    New clinical milestone for a second obesity candidate diversifies Viking's pipeline and future revenue potential.

  • VK2735 Phase 3 data expected 2027 Viking's lead obesity drug VK2735 is in Phase 3 trials, with top-line data expected no earlier than 2027. Phase 2 results showed up to 14.7% weight loss, competitive but behind rivals like Eli Lilly's retatrutide (28.3%). Success could unlock a $100 billion market.

    The timing and potential of VK2735's Phase 3 data are central to Viking's valuation and investor expectations.

  • Stock gained 19.2% in June on pipeline optimism Viking shares rose 19.2% in June as investors grew optimistic about the weight-loss pipeline. The rally was fueled by Phase 2 results, pipeline advancements, and sector tailwinds. However, the stock remains volatile and high-risk, with no approved products yet.

    Summarizes the period's strong stock performance and the underlying drivers, giving a big-picture view.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

© 2026 MarketIVWhy